Find Reports

Select Report Type

Reimbursement Review

Displaying 451 - 475 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
insulin degludec + liraglutide	Xultophy	insulin degludec + liraglutide	SR0599 Xultophy - CDEC Final Recommendation October 28, 2019_redacted_For posting.pdf sr0599-xultophy-clinical-review-report.pdf sr0599-xultophy-pharmacoeconomic-review-report.pdf SR0599-Xultopy-Patient-Input.pdf	Diabetes mellitus, Type 2	Reimburse with clinical criteria and/or conditions	Complete	Jan 30, 2019	Oct 24, 2019	SR0599-000
onabotulinumtoxinA	Botox	onabotulinumtoxinA	SR0584 Botox Resubmission - CDEC Final Recommendation October 22, 2019_for posting.pdf sr0584-botox-clinical-review-report-resubmission.pdf sr0584-botox-pharmacoeconomic-review-report-resubmission.pdf SR0584 Botox Resubmission - Consolidated Patient Input_Dec 2018_Redacted.pdf	Migraine, chronic	Reimburse with clinical criteria and/or conditions	Complete	Nov 2, 2018	Oct 17, 2019	SR0584-000
Keytruda Metastatic Urothelial...	Keytruda	Pembrolizumab	PembrolizumabKeytruda_MUCfirstline10177ProvFunding.pdf 10177PembrolizumabMUC(firstline)_FnRec_REDACT_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_fnEGR_NOREDACT-ABBREV_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_fnCGR_REDACT_Post_03Oct2019_final.pdf 10177PembrolizumabMM(first line)_InRec_REDACT_Post_01Aug2019_final.pdf 10177PembrolizumabMUC(firstline)_PAGFeedbackSummary_FINAL_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_SubmitterFeedback_2019-08-16_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_PatientFeedback_BCC_2019-08-16__Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_ClinicianFeedback_CCO_2019-08-16_Post_03Oct2019_final.pdf 10177PembrolizumabMUC(firstline)_PtGrp_COI_Post_03Oct2019_final_Redacted.pdf 10177PembrolizumabMUC(firstline)_Combined ClinicianCOIs_Post_03Oct2019_final.pdf	MUC First line	Do not reimburse	Complete	Feb 20, 2019	Oct 3, 2019	PC0177-000
dolutegravir / lamivudine	Dovato	dolutegravir / lamivudine	SR0601 Dovato - CDEC Final Recommendation October 2, 2019_for posting.pdf sr0601-dovato-clinical-review-report.pdf sr0601-dovato-pharmacoeconomic-review-report.pdf sr0601-dovato-patient-input.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Feb 21, 2019	Sep 30, 2019	SR0601-000
fluocinolone acetonide intravi...	Iluvien	fluocinolone acetonide intravitreal implant	SR0608 Iluvien - CDEC Final Recommendation September 30, 2019_for posting.pdf sr0608-iIluvien-clinical-review-report.pdf sr0608-iIluvien-pharmacoeconomic-review-report.pdf SR0608-Iluvien-patient-input.pdf	diabetic macular edema	Do not reimburse	Complete	Apr 3, 2019	Sep 26, 2019	SR0608-000
Pomalyst in combination with d...	Pomalyst	Pomalidomide	PomalidomidePomalystDex&Bortez_MM2ndline10165_ProvFunding.pdf 10165PomalidomideBortezomibMM_fnRec_EarlyConv_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_fnEGR_NOREDACT-ABBREV_EarlyConv_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_fnCGR_REDACT_EarlyConv_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_InRec_approvedbyChair_Post_29Aug2019_final.pdf 10165PomalidomideBortezomibMM_PAGFeedbackSummary_FINAL_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_SubmitterFeedback_2019-09-13_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_ClinicianFeedback_CCO_2019-09-09_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_COI_Post_18Sep2019_final.pdf 10165PomalidomideBortezomibMM_Combined Clinician_COI_Post_18Sep2019_final.pdf	Multiple Myeloma	Reimburse with clinical criteria and/or conditions	Complete	Mar 15, 2019	Sep 18, 2019	PC0165-000
Trifluridine and Tipiracil (Lo...	Lonsurf	Trifluridine and Tipiracil	pcodr_provfund-10173-trifluridine-tipiracil_lonsurf_mcrc.pdf 10173Trifluridine-TipiracilmCRC_fnrec_Chair Approved_Post_29Aug2019_revised_final.pdf 10173Trifluridine-TipiracilmCRC_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_fnCGR_NOREDACT_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_inRec_Chair approved_NOREDACT_Post_05Jul2019_final.pdf 10173Trifluridine-TipiracilmCRC_PAGFeedbackSummary_FINAL_2019-07-15_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_PatientFeedback_CCC_2019-07-19_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_ClinicianFeedback_Ko_2019-07-19_Post_29Aug2019_final.pdf 10173Trifluridine-TipiracilmCRC_Patient COIs_Post_29Aug2019_final_Redacted.pdf 10173Trifluridine-TipiracilmCRC_Clinicians COIs_Post_29Aug2019_final_Redacted.pdf	mCRC Resubmission	Do not reimburse	Complete	Jan 21, 2019	Aug 29, 2019	PC0173-000
Darzalex in combo with Bortezo...	Darzalex	Daratumumab	DaratumumabDarzalex_NewlyDiagnosedMM10148_ProvFunding.pdf 10148Daratumumab+VMPforMM_fnRec_REDACT_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_fnCGR_REDACT_Post_29Aug2910_final.pdf 10148Daratumumab+VMPforMM_inRec_ApprovedbyChair_REDACT_Post_05Jul2019_final.pdf 10148Daratumumab+VMPforMM_PAGFeedbackSummary_FINAL_2019-07-16_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_PatientFeedback_MC_2019-07-08_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_ClinicianFeedback_CCO_2019-07-15_Post_29Aug2019_final.pdf 10148Daratumumab+VMPforMM_PatientI_COI_Post_29Aug2019.pdf 10148Daratumumab+VMPforMM_Combined Clinician COIs_Post_28Aug2019_Redacted.pdf	BMP for Multiple Myeloma (newly diagnosed)	Reimburse with clinical criteria and/or conditions	Complete	Jan 4, 2019	Aug 29, 2019	PC0148-000
baricitinib	Olumiant	baricitinib	SR0597 Olumiant - Patient Group Input_February 7, 2019.pdf sr0597-olumiant-clinical-review-report.pdf sr0597-olumiant-pharmacoeconomic-review-report.pdf SR0597 Olumiant - CDEC Final Recommendation_for posting.pdf	Arthritis, Rheumatoid	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2018	Aug 2, 2019	SR0597-000
Lutathera for Gastroenteropanc...	Lutathera	Lutetium Lu 177 dotatate	pcodr-provfund-10142-LutetiumLutathera_GEP_NETs.pdf 10142LutetiumLu177dotatateGEP-NET_fnRec_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_fnCGR_NOREDACT_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_PAGFeedbackSummary_FINAL_Post_01Aug2019_draft.pdf 10142LutetiumLu177dotatateGEP-NET_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_PatientFeedback_CNETS_2019-06-28_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_COI_Post_01Aug2019_final.pdf	Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	Reimburse with clinical criteria and/or conditions	Complete	Jul 30, 2018	Aug 1, 2019	PC0142-000
Brigatinib (Alunbrig) for Non-...	Alunbrig	Brigatinib	pcodr_provfund-10167-BrigatinibAlunbrig_NSCLC.pdf 10167BrigatinibNSCLC_FnRec_approvedbyChair_NOREDACT_Post_01AUG2019_final.pdf 10167BrigatinibNSCLC_fnEGR_NOREDACT-ABBREV_01AUG2019_final.pdf 10167BrigatinibNSCLC_fnCGR_NOREDACT_POST01AUG2019_final.pdf 10167BrigatinibNSCLC_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf 10167BrigatinibNSCLC_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_PatientFeedback_LCC_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_Combined_ClinicianFeedback_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_Combined_PtGrp_COIs_Post_01Aug2019_final_Redacted.pdf 10167BrigatinibNSCLC_Combined_Clinician_COIs_01Aug2019_final_Redacted.pdf	NSCLC	Do not reimburse	Complete	Dec 5, 2018	Aug 1, 2019	PC0167-000
Keytruda for Melanoma Adjuvant...	Keytruda	Pembrolizumab	pcodr_provfund-10168-PembrolizumabKeytruda_MAT.pdf 10168PembrolizumabMAT_FnRec_31 July 2019__Post_01Aug2019_final.pdf 10168PembrolizumabMAT_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_fnCGR_REDACT_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10168PembolizumabMAT_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_SubmitterFeedback_2019-06-12_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_ClinicianFeedback_CCO_2019-06-14_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_Combined_Patient_COIs_Post_01Aug2019_final_Redacted.pdf 10168PembrolizumabMAT_Combined_Clinician_COIs_Post_01Aug2019_final.pdf	Melanoma Adjuvant Treatment	Reimburse with clinical criteria and/or conditions	Complete	Dec 13, 2018	Aug 1, 2019	PC0168-000
patisiran	Onpattro	patisiran	SR0598_Onpattro-patient-input.pdf SR0598 Onpattro - CDEC Final Recommendation July 29, 2019 for posting.pdf sr0598-onpattro-clinical-review-report.pdf sr0598-onpattro-pharmacoeconomic-review-report.pdf	Polyneuropathy in hereditary transthyretin-mediated amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Jan 25, 2019	Jul 25, 2019	SR0598-000
ulipristal acetate	Fibristal	ulipristal acetate	SF0609 Fibristal - Group Patient Input June 28, 2019.pdf SF0609 Fibristal RfA - CDEC Final Recommendation July 30, 2019_for posting.pdf sf0609-fibristal-request-for-advice-clinical-review-report.pdf	Uterine fibroids (signs and symptoms)	Reimburse with clinical criteria and/or conditions	Complete	Mar 28, 2019	Jul 24, 2019	SF0609-000
Latanoprostene bunod	Vyzulta	latanoprostene bunod	sr0590-vyzulta-clinical-review-report.pdf sr0590-vyzulta-pharmacoeconomic-review-report.pdf sr0590-vyzulta-patient-input.pdf SR0590 Vyzulta - CDEC Final Recommendation July 26, 2019 _for posting.pdf	Open-angle glaucoma or ocular hypertension	Reimburse with clinical criteria and/or conditions	Complete	Nov 23, 2018	Jul 24, 2019	SR0590-000
Lenvima for Hepatocellular Car...	Lenvima	Lenvatinib	pcodr-profund-10175-LenvatinibLenvima_HCC.pdf 10175LenvatinibHCC_fnRec_2019-07-23_ApprovedByChair_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inEGR_NOREDACT-ABBREV_EarlyCon_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inCGR_NOREDACT_EarlyConv_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inRec_ApprovedByChair_NOREDACT_Post_05Jul2019_final.pdf 10175LenvatinibHCC_PAGFeedbackSummary_FINAL_Post_24Jul2019_final.pdf 10175LenvatinibHCC_SubmitterFeedback_2019-07-19_Post_24Jul2019_final.pdf 10175LenvatinibHCC_Canadian Liver Foundation v2 2019-07-22_Post_24Jul2019_final.pdf 10175LenvatinibHCC_ClinicianFeedback_BCCancer_2019-07-18_Post_24Jul2019_final.pdf 10175LenvatinibHCC_CombinedPat_Post_24Jul2019_Redacted.pdf 10175LenvatinibHCC_Combined Clinician COIs_Post_24Jul2019_final.pdf	Hepatocellular Carcinoma (HCC)	Reimburse with clinical criteria and/or conditions	Complete	Feb 8, 2019	Jul 24, 2019	PC0175-000
Ninlaro for Multiple Myeloma (...	Ninlaro	Ixazomib	pcodr-provfund-10164-ixazomib-ninlaro_mm2nd-beyond.pdf 10164IxazomibMM_fnRec_2019-07-05_ChairApproved_Post_05Jul2019_final.pdf 10164IxazomibMM_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf 10164IxazomibMM_fnCGR_REDACT_Post_05Jul2019_final.pdf 10164IxazomibMM_inRec_2019-05-03_Approved_Post_03May2019_final.pdf 10164IxazomibMM_PAGFeedbackSummary_FINAL_Post_5Jul2019_final.pdf 10164IxazomibMM_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf 10164IxazomibMM_PatientFeedback_MC_2019-05-15_Post_05Jul2019_final.pdf 10164IxazomibMM_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf 10164IxazomibMM_Patient_COI_MC_2018-12-13_Post_05Jul2019_final_Redacted.pdf 10164IxazomibMM_Combined COIs_Post_05Jul2019_final Redacted.pdf	Multiple Myeloma (2nd-beyond)	Do not reimburse	Complete	Nov 30, 2018	Jul 5, 2019	PC0164-000
Abemaciclib for advanced or me...	Verzenio	Abemaciclib	pcodr-provfund-10161-AbemaciclibVerzenio_ABC.pdf 10161AbemaciclibMBC_fnRec_ApprovedbyChair_v01_2019-07-04_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_fnCGR_NOREDACT_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_inRec_ApprovedbyChair_v01_Post_03May2019_final.pdf 10161AbemaciclibMBC_PAGFeedbackSummary_FINAL_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined PatientFeedback_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined Patient COIs_ Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined COIs_Post_05Jul2019_final.pdf	Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 3, 2018	Jul 5, 2019	PC0161-000
telotristat	Xermelo	telotristat	SR0580_telotristat_PI Submission.pdf SR0580 Xermelo - CDEC Final Recommendation July 3, 2019_For Posting.pdf sr0580-xermelo-clinical-review-report.pdf sr0580-xermelo-pharmacoeconomic-review-report.pdf	carcinoid syndrome	Do not reimburse	Complete	Sep 27, 2018	Jun 26, 2019	SR0580-000
buprenorphine	Sublocade	buprenorphine	SR0579 Sublocade - CDEC Final Recommendation June 21, 2019_for posting.pdf sr0579-sublocade-clinical-review-report.pdf sr0579-sublocade-pharmacoeconomic-review-report.pdf	Opioid use disorder, treatment	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2018	Jun 19, 2019	SR0579-000
Revlimid (in combo) bortezomib...	Revlimid	Lenalidomide	pcodr-provfund-10141-LenalidomideRevlimid_MM.pdf 10141LenalidomideBorDexMM_fnRec_2019-06-19_ApprovedbyChair_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_fnEGR_NOREDACT-ABBREV_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_fnCGR_REDACT_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf 10141LenalidomideBorDexMM_PAGFeedbackSummary_FINAL__EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_SubmitterFeedback_2019-06-14_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_ClinicianFeedback_CCO_2019-06-14__EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_PatientCOI_MC_2019-01-11_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_Clinician_Combined_COIs_Post_19Jun2019_final_Redacted.pdf	Multiple Myeloma (+bortezomib+dex)	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2018	Jun 19, 2019	PC0141-000
cysteamine	Cystadrops	cysteamine	SR0595 Cystadrops - CDEC Final Recommendation June 20, 2019_for posting.pdf sr0595-cystadrops-clinical-review-report.pdf sr0595-cystadrops-pharmacoeconomic-review-report.pdf	Corneal cystine crystal deposits	Reimburse with clinical criteria and/or conditions	Complete	Dec 10, 2018	Jun 18, 2019	SR0595-000
Keytruda for Non-Squamous NSCL...	Keytruda	Pembrolizumab	pcodr-provfund-10153-pembrolizumab-keytruda-non-squamous_nsclc.pdf 10153PembroNSQ-NSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10153PembroNSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_fnCGR_REDACT_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_InRec_POST04Apr2019_NOREDACT_corrected.pdf 10153PembroNSQ-NSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_Patient_Combined COIs_ForPosting_31May2019.pdf 10153PembroNSQ-NSCLC_Clinician_Combined COIs_Post_31May2019_final.pdf	Nonsquamous NSCLC	Reimburse with clinical criteria and/or conditions	Complete	Sep 14, 2018	May 31, 2019	PC0153-000
Venclexta in combo Rituximab f...	Venclexta in combo Rituximab	Venetoclax	pcodr_provfund_10162_venetoclax_venclexta_and_rituximab.pdf 10162VenetoclaxRituximabCLL_FnRec_approvedbyChair_REDACT_Post_31May2019-final.pdf 10162VenetoclaxRituximabCLL_fnEGR_NOREDACT-ABBREV_31May2019_final.pdf 10162VenetoclaxRituximabCLL_fnCGR_REDACT_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_InRec_POST04Apr2019_REDACT_final.pdf 10162VenetoclaxRituximabCLL_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_PatientFeedback_LC_CLLPAG_2019-04-17_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_Patient_Combined_COIs_Post_31May2019_final.pdf 10162VenetoclaxRituximabCLL_Clinician_Combined_COIs_Post_31May2019_final.pdf	Chronic Lymphocytic Leukemia (CLL)	Reimburse with clinical criteria and/or conditions	Complete	Oct 24, 2018	May 31, 2019	PC0162-000
Vizimpro for Non-Small Cell Lu...	Vizimpro	Dacomitinib	pcodr-provfund-10129-dacomitinib-vizimpro.pdf 10129DacomitinibNSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10129DacomitinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10129DacomitinibNSCLC_fnCGR_NOREDACT_Post_31May2019_final.pdf 10129DacomitinibNSCLC_InRec_POST04Apr2019_NOREDACT_final.pdf 10129DacomitinibNSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10129DacomitinibNSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_Patient_Combined_COIs_ForPosting_31May2019_final.pdf 10129DacomitinibNSCLC_Clinician_Combined_COIs_Post_31May2019_final.pdf	Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Sep 19, 2018	May 31, 2019	PC0129-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 451 - 475 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Wearable Devices for Monitoring and Detecting COVID-19 Symptoms	Wearable Devices for Monitoring and Detecting COVID-19 Symptoms	Sep 30, 2020	Health Technology Update	Completed	EN0021-000
Interventions for the Prevention of Sudden Infant Death Syndrome and Sudden Unexplained Death in Infancy: A Review of Guidelines	RC1307 SIDS Prevention Final.pdf	Sep 28, 2020	Summary with Critical Appraisal		RC1307-000
Flash Glucose Monitoring System FreeStyle Libre to Monitor Glycemia in Patients With Diabetes	ho0009-tech-review-flash-glucose-monitoring-system-freestyle-libre.pdf ho0009-fgms-implementation-advice-report.pdf	Sep 24, 2020	Technology Review	Completed	HO0009-000
Nusinersen for Adolescents and Adults with Spinal Muscular Atrophy: A Review of Clinical Effectiveness	RD0056 Spinraza for SMA Final.pdf	Sep 22, 2020	Rapid Review with Expert Input	Completed	RD0056-000
Fecal Microbiota Therapy in Canada: Barriers and Facilitators to Access		Sep 17, 2020	Environmental Scan	Completed	ES0341-000
Fecal Microbiota Therapy in Canada: An Environmental Scan		Sep 17, 2020	Environmental Scan	Completed	ES0341-000
Enablers for Virtual Visits	Enablers for Virtual Visits	Sep 4, 2020	Policy Insight	Completed	CY0006-000
Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement: A Review of Clinical Effectiveness and Guidelines	RC1304 ASA for VTE Final.pdf	Aug 31, 2020	Summary with Critical Appraisal		RC1304-000
Hypodermoclysis for Frail Patients and Patients in Long Term Care: A Review of Clinical Effectiveness, Cost Effectiveness, and Guidelines	Hypodermoclysis for Frail Patients and Patients in Long Term Care: A Review of …	Aug 31, 2020	Summary with Critical Appraisal	Completed	RC1306-000
Comparative Assessment of Coverage Criteria for Biologic Disease-Modifying Antirheumatic Drugs Across Canadian Public Drug Plans: An Environmental Scan		Aug 27, 2020			ES0351-000
Immediately Sequential Bilateral Cataract Surgery for the Treatment of Bilateral Cataracts: A Review of Safety and Guidelines	media:document:4bb2d7e7-a61a-4e25-b2dc-d88d44011da5	Aug 25, 2020	Summary with Critical Appraisal		RC1305-000
Technologies to Address the Negative Effects of Social Isolation for Older Adults Living in Long-Term Care	Technologies to Address the Negative Effects of Social Isolation for Older Adul…	Aug 17, 2020	Health Technology Update	Completed	EN0024-000
Sex Offender Treatment Programs Delivered In-Person or Virtually for Adults Convicted of Sexual Offences in Various Settings: A Review of Clinical Effectiveness and Guidelines	RC1300 Sex Offender Treatment Final.pdf	Aug 17, 2020	Summary with Critical Appraisal		RC1300-000
Ketamine for Sedation During Bronchoscopy Procedures: A Review of Clinical Effectiveness, Safety, and Guidelines	RC1298 Bronchoscopy Ketamine Final.pdf	Aug 17, 2020	Summary with Critical Appraisal		RC1298-000
Short-Acting Sedative Agents During Endoscopic Retrograde Cholangiopancreatography: A Review of Clinical Effectiveness and Guidelines	media:document:472ad0bd-2634-46fc-b006-8807d4bdaeae	Aug 17, 2020	Summary with Critical Appraisal		RC1301-000
e-Consult for Primary Care Clinician Access to Specialists	e-Consult for Primary Care Clinician Access to Specialists Inter-jurisdictional Medical Licensing to Support Telemedicine	Aug 13, 2020	Health Technology Assessment	Completed	HT0030-000
Pegylated Interferon Alfa 2a Therapy in Patients with Myeloproliferative Disorders: A Review of Clinical Effectiveness and Cost-Effectiveness	Pegylated Interferon Alfa 2a Therapy in Patients with Myeloproliferative Disord…	Aug 5, 2020	Summary with Critical Appraisal		RC1299-000
Ondansetron in Patients Requiring Anti-Emetics: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1297 Ondansetron in Patients Requiring Anti-Emetics Final.pdf	Aug 4, 2020	Summary with Critical Appraisal		RC1297-000
Needleless Injectors for the Administration of Vaccines: A Review of Clinical Effectiveness	RC1296-000 Needleless Injector Final.pdf	Jul 17, 2020	Summary with Critical Appraisal	Completed	RC1296-000
Topical Wound Oxygen Therapy for Wound Healing: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	Summary With Critical Appraisal - Rapid Response Report	Jul 17, 2020	Summary with Critical Appraisal	Completed	RC1292-000
Vancomycin Therapeutic Drug Monitoring	ha0006-vancomycin-fca-final.pdf	Jul 16, 2020	Technology Review	Completed	HA0006-000
Capsaicin for Acute or Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness	RC1294 Capsaicin for NCP C and CE Final.pdf	Jul 13, 2020	Summary with Critical Appraisal	Completed	RC1294-000
Healthy Aging Interventions, Programs, and Initiatives: An Environmental Scan	Healthy Aging Interventions, Programs, and Initiatives: An Environmental Scan	Jul 10, 2020	Environmental Scan	Completed	ES0342-000
Conservative Management of Chronic Kidney Disease in Adult Patients: A Review of Clinical Effectiveness and Cost-Effectiveness	media:document:03abba0f-fdd5-44a8-900c-07630c85eab0	Jul 10, 2020	Summary with Critical Appraisal		RC1276-000
Tuberculosis	ht0033-tuberculosis-project-plan.pdf ht0033-tuberculosis-policy-insights-final.pdf	Jul 2, 2020	Health Technology Assessment	Completed	HT0033-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 451 - 475 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Pharmaceutical Reviews Update — Issue 46			Apr 24, 2024	Reimbursement Review	Pharmaceutical Review Update
glofitamab		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 22, 2024	Reimbursement Review		Complete	PC0320-000
SGLT2 inhibitors for the treatment of type 2 diabetes			Apr 18, 2024	Health Technology Review	Technology Review	Cancelled	HC0049-000
evinacumab		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Apr 17, 2024	Reimbursement Review		Complete	SR0778-000
Buprenorphine-Based Formulations for Opioid Use Disorder in Correctional Settings	Various formulations of buprenorphine, including extended-release depot injection and transmucosal tablet and film, are used to treat opioid use disorder. Our Environmental Scan explores the provision of these formulations in correctional settings.	Final Report Summary report	Apr 15, 2024	Horizon Scan	Environmental Scan	Complete	ES0380-000
imiquimod			Apr 15, 2024	Reimbursement Review		Withdrawn	PX0364-000
HR positive, HER2 negative breast cancer		Final Report	Apr 10, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0041-000
Renal Denervation		Renal Denervation	Apr 10, 2024	Health Technology Review	Rapid Review	Completed	RC1532-000
Large B cell lymphoma		Final Report	Apr 9, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0040-000
efgartigimod alfa		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 8, 2024	Reimbursement Review		Complete	SR0782-000
Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria		Final Report Final Summary Report	Apr 4, 2024	Health Technology Review	Technology Review	Completed	HC0053-000
ibrutinib		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Apr 2, 2024	Reimbursement Review		Complete	PC0328-000
calaspargase pegol		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Apr 2, 2024	Reimbursement Review		Complete	PC0321-000
Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease			Apr 1, 2024	Health Technology Review	Technology Review	In Progress	HC0086 -000
Prostate Cancer		Final Report	Mar 28, 2024	Reimbursement Review	Provisional Funding Algorithm	Completed	PH0039-000
CADTH Pharmaceutical Reviews Update — Issue 45			Mar 28, 2024	Reimbursement Review	Pharmaceutical Review Update
semaglutide		Recommendation and Reasons: Updated Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Mar 22, 2024	Reimbursement Review		Complete	SR0594-000
semaglutide		Recommendation and Reasons: Updated Recommendation and Reasons - Original Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Mar 22, 2024	Reimbursement Review		Complete	SR0637-000
Empagliflozin and metformin		Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Patient Group Input Submissions Clinical Report Pharmacoeconomic Report	Mar 22, 2024	Reimbursement Review		Complete	SR0489-000
dulaglutide		Recommandation et motifs : Rapport mise à jour Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Mar 22, 2024	Reimbursement Review		Complete	SR0462-000
dapagliflozin/metformin hydrochloride		Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Patient Group Input Submissions Fixed‐Dose Combination Report Summary Report	Mar 22, 2024	Reimbursement Review		Complete	SR0468-000
Empagliflozin		Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Mar 22, 2024	Reimbursement Review		Complete	SR0427-000
Dapagliflozin		Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Mar 22, 2024	Reimbursement Review		Complete	SR0428-000
Saxagliptin		Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report	Mar 22, 2024	Reimbursement Review		Complete	SR0329-000
Saxagliptin + Metformin		Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Fixed-Dose Combination Review Report	Mar 22, 2024	Reimbursement Review		Complete	SR0348-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81